12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Lugol’s solution and other iodide preparations: perspectives and research directions in Graves’ disease

      research-article
      1 , 2 , , 1 , 2
      Endocrine
      Springer US
      Hyperthyroidism, Thyroidectomy, Iodide, Adjuvant treatment, Escape

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Lugol’s solution and other preparations containing iodide have for almost a century been used as an adjuvant treatment in patients with Graves’ disease planned for thyroidectomy. Iodide has been shown to decrease thyroid hormone levels and reduce blood flow within the thyroid gland. An escape phenomenon has been feared as the iodide effect has been claimed to only be temporary. Lugol’s solution has many additional effects and is used in other settings beside the thyroid. Still, there are questions of its mode of action, which doses should be deployed, if it should be used preoperative in all thyroidectomies or only in a few selected ones if at all, what is its use in other forms of thyrotoxicosis besides Graves’ disease, and what is the mechanism acting on the vasculature and if these effects are confined only to arterial vessels supporting the thyroid or not. This review aims to collate current available data about Lugol’s solution and other iodide preparations in the management of Graves’ disease and give some suggestions where more research is needed.

          Related collections

          Most cited references53

          • Record: found
          • Abstract: found
          • Article: not found

          Iodine-Induced hypothyroidism.

          Iodine is an essential element for thyroid hormone synthesis. The thyroid gland has the capacity and holds the machinery to handle the iodine efficiently when the availability of iodine becomes scarce, as well as when iodine is available in excessive quantities. The latter situation is handled by the thyroid by acutely inhibiting the organification of iodine, the so-called acute Wolff-Chaikoff effect, by a mechanism not well understood 52 years after the original description. It is proposed that iodopeptide(s) are formed that temporarily inhibit thyroid peroxidase (TPO) mRNA and protein synthesis and, therefore, thyroglobulin iodinations. The Wolff-Chaikoff effect is an effective means of rejecting the large quantities of iodide and therefore preventing the thyroid from synthesizing large quantities of thyroid hormones. The acute Wolff-Chaikoff effect lasts for few a days and then, through the so-called "escape" phenomenon, the organification of intrathyroidal iodide resumes and the normal synthesis of thyroxine (T4) and triiodothyronine (T3) returns. This is achieved by decreasing the intrathyroidal inorganic iodine concentration by down regulation of the sodium iodine symporter (NIS) and therefore permits the TPO-H202 system to resume normal activity. However, in a few apparently normal individuals, in newborns and fetuses, in some patients with chronic systemic diseases, euthyroid patients with autoimmune thyroiditis, and Graves' disease patients previously treated with radioimmunoassay (RAI), surgery or antithyroid drugs, the escape from the inhibitory effect of large doses of iodides is not achieved and clinical or subclinical hypothyroidism ensues. Iodide-induced hypothyroidism has also been observed in patients with a history of postpartum thyroiditis, in euthyroid patients after a previous episode of subacute thyroiditis, and in patients treated with recombinant interferon-alpha who developed transient thyroid dysfunction during interferon-a treatment. The hypothyroidism is transient and thyroid function returns to normal in 2 to 3 weeks after iodide withdrawal, but transient T4 replacement therapy may be required in some patients. The patients who develop transient iodine-induced hypothyroidism must be followed long term thereafter because many will develop permanent primary hypothyroidism.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Plasma inorganic iodide as a homeostatic regulator of thyroid function.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Incidence of hyperthyroidism in Sweden.

              The incidence of hyperthyroidism has been reported in various countries to be 23-93/100,000 inhabitants per year. This extended study has evaluated the incidence for ~40% of the Swedish population of 9 million inhabitants. Sweden is considered to be iodine sufficient country.
                Bookmark

                Author and article information

                Contributors
                +46851770000 , jan.calissendorff@sll.se
                Journal
                Endocrine
                Endocrine
                Endocrine
                Springer US (New York )
                1355-008X
                1559-0100
                26 October 2017
                26 October 2017
                2017
                : 58
                : 3
                : 467-473
                Affiliations
                [1 ]ISNI 0000 0000 9241 5705, GRID grid.24381.3c, Department of Endocrinology, Metabolism and Diabetes, , Karolinska University Hospital, ; Stockholm, Sweden
                [2 ]ISNI 0000 0004 1937 0626, GRID grid.4714.6, Department of Molecular Medicine and Surgery, , Karolinska Institutet, ; Stockholm, Sweden
                Article
                1461
                10.1007/s12020-017-1461-8
                5693970
                29075974
                6f9099e1-44e2-41ce-afb0-4b91f70919ef
                © The Author(s) 2017

                This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

                History
                : 11 August 2017
                : 17 October 2017
                Categories
                Endocrine Surgery
                Custom metadata
                © Springer Science+Business Media, LLC, part of Springer Nature 2017

                Endocrinology & Diabetes
                hyperthyroidism,thyroidectomy,iodide,adjuvant treatment,escape
                Endocrinology & Diabetes
                hyperthyroidism, thyroidectomy, iodide, adjuvant treatment, escape

                Comments

                Comment on this article